EP4540285A4 - Humanisierte antikörper gegen menschlichen neurotensinrezeptor 1 und deren verwendungen - Google Patents

Humanisierte antikörper gegen menschlichen neurotensinrezeptor 1 und deren verwendungen

Info

Publication number
EP4540285A4
EP4540285A4 EP22970346.7A EP22970346A EP4540285A4 EP 4540285 A4 EP4540285 A4 EP 4540285A4 EP 22970346 A EP22970346 A EP 22970346A EP 4540285 A4 EP4540285 A4 EP 4540285A4
Authority
EP
European Patent Office
Prior art keywords
antibodies against
humanized antibodies
against human
neurotensin receptor
human neurotensin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22970346.7A
Other languages
English (en)
French (fr)
Other versions
EP4540285A1 (de
Inventor
Cheng-Chou Yu
Shu-Ping Yeh
Chao-Yang Huang
Szu-Liang Lai
Shih-Liang Hsiao
Mei-Ling Hou
Tzung-Jie Yang
Wei-Ting Sun
Liang-Yu Hsia
Andrew Yueh
Chiung-Tong Chen
Ren-Huang Wu
Pei-Shan Wu
Han-Shu Hu
Tzu-Chin Wu
Jia-Ni Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Development Center for Biotechnology
National Health Research Institutes
Original Assignee
Development Center for Biotechnology
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Development Center for Biotechnology, National Health Research Institutes filed Critical Development Center for Biotechnology
Publication of EP4540285A1 publication Critical patent/EP4540285A1/de
Publication of EP4540285A4 publication Critical patent/EP4540285A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP22970346.7A 2022-12-28 2022-12-28 Humanisierte antikörper gegen menschlichen neurotensinrezeptor 1 und deren verwendungen Pending EP4540285A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2022/082472 WO2024144803A1 (en) 2022-12-28 2022-12-28 Humanized anti-human neurotensin receptor 1 antibodies and their uses

Publications (2)

Publication Number Publication Date
EP4540285A1 EP4540285A1 (de) 2025-04-23
EP4540285A4 true EP4540285A4 (de) 2025-10-08

Family

ID=91719018

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22970346.7A Pending EP4540285A4 (de) 2022-12-28 2022-12-28 Humanisierte antikörper gegen menschlichen neurotensinrezeptor 1 und deren verwendungen

Country Status (6)

Country Link
EP (1) EP4540285A4 (de)
JP (1) JP2025529623A (de)
KR (1) KR20250123220A (de)
CN (1) CN119790070A (de)
AU (1) AU2022491825A1 (de)
WO (1) WO2024144803A1 (de)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016189091A1 (en) * 2015-05-26 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112678A1 (en) * 2003-11-24 2005-05-26 Amgen Inc. Gene amplification and overexpression in cancer
AU2014415566A1 (en) * 2014-12-31 2017-07-20 Develpment Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
EP3844173A1 (de) * 2018-08-31 2021-07-07 Immune Biosolutions Inc. Antikörper mit spezifität für ntsr1 und verwendungen davon
CN113164780A (zh) * 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
TWI781647B (zh) * 2020-06-09 2022-10-21 財團法人國家衛生研究院 抗人神經降壓素受體抗體及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016189091A1 (en) * 2015-05-26 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHRISTOU NIKI ET AL: "Neurotensin pathway in digestive cancers and clinical applications: an overview", CELL DEATH & DISEASE, vol. 11, no. 12, 1 January 2020 (2020-01-01), pages 1027, XP093024410, Retrieved from the Internet <URL:https://www.nature.com/articles/s41419-020-03245-8.pdf> DOI: 10.1038/s41419-020-03245-8 *
SATOYA SHIMIZU ET AL: "Identification of a novel therapeutic target for head and neck squamous cell carcinomas: A role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 123, no. 8, 25 July 2008 (2008-07-25), pages 1816 - 1823, XP071284959, ISSN: 0020-7136, DOI: 10.1002/IJC.23710 *
See also references of WO2024144803A1 *

Also Published As

Publication number Publication date
CN119790070A (zh) 2025-04-08
WO2024144803A1 (en) 2024-07-04
WO2024144803A8 (en) 2024-10-10
AU2022491825A1 (en) 2025-08-07
EP4540285A1 (de) 2025-04-23
JP2025529623A (ja) 2025-09-09
KR20250123220A (ko) 2025-08-14

Similar Documents

Publication Publication Date Title
EP4141029A4 (de) Antikörper gegen nectin-4 und anwendung davon
EP4271413A4 (de) Monoklonaler antikörper gegen menschlichen mac-1 und dessen verwendungen
EP4282880A4 (de) Vollständig menschlicher breitspektrumneutralisierender antikörper 26e1 gegen coronavirus und verwendung davon
EP4332116A4 (de) Anti-cntn4-spezifische antikörper und deren verwendung
EP4205764A4 (de) Anti-trunkierter mutanter bispezifischer calr-cd3-antikörper und pharmazeutische zusammensetzung
EP4499707A4 (de) Anti-ccr8-antikörper und verwendungen davon
EP4139347A4 (de) Anti-cd3-antikörper und verwendungen davon
EP4380631A4 (de) Gegen cd3 gerichtete antikörper und verwendungen davon
EP4105238A4 (de) Claudin-18.2-antikörper und deren verwendung
EP4359442A4 (de) Anti-ccr8-antikörper und verwendungen davon
EP4105237A4 (de) Cldn18.2-antikörper und verwendung davon
EP4301784A4 (de) Antikörper gegen claudin-6 und verwendungen davon
IL286696A (en) Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
EP4142793A4 (de) Abcb5-spezifische antikörper und verwendungen davon
EP4126938A4 (de) Siglec15-bindende antikörper und verwendungen davon
EP4393954A4 (de) Monoklonaler anti-tnfr2-antikörper und anwendung davon
EP4244255A4 (de) Anti-tigit-antikörper und verwendungen davon
EP4132569A4 (de) Anti-phf-tau-antikörper und verwendungen davon
EP4164388A4 (de) Antikörper gegen menschlichen neurotensinrezeptor 1 und verwendung davon
EP4247419A4 (de) Anti-marco-antikörper und verwendungen davon
EP4415727A4 (de) Chimäre anti-steap2-antigenrezeptoren und verwendungen davon
EP4396224A4 (de) Anti-dll3-antikörper und verwendungen davon
LT4288456T (lt) Antikūnai prieš met ir jų panaudojimas
EP4146272A4 (de) Covid-19-antikörper und verwendungen davon
EP4200337A4 (de) Antikörper gegen trop2 und cd3 und verwendungen davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250119

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

A4 Supplementary search report drawn up and despatched

Effective date: 20250909

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20250903BHEP

Ipc: A61K 39/00 20060101ALI20250903BHEP

Ipc: A61K 39/39 20060101ALI20250903BHEP

Ipc: A61K 39/395 20060101ALI20250903BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)